The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FLDM | -48.17% | -85.05% | -31.59% | -92% |
| S&P | +12.65% | +91.73% | +13.89% | +409% |
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
The company reported disappointing fourth-quarter results.
The company is now cleared to sell its saliva-based COVID-19 test in Europe.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $19.55M | -56.5% |
| Gross Profit | $9.48M | -59.2% |
| Gross Margin | 48.51% | -3.2% |
| Market Cap | $496.59M | -30.7% |
| Market Cap / Employee | $0.61M | 0.0% |
| Employees | 818 | 51.8% |
| Net Income | -$31.68M | -17.6% |
| EBITDA | -$21.87M | -6.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $129.42M | -38.6% |
| Accounts Receivable | $13.54M | -61.7% |
| Inventory | 25.4 | -40.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.28M | -21.7% |
| Short Term Debt | $5.11M | -91.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -17.93% | 6.5% |
| Return On Invested Capital | -35.38% | 0.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.09M | 23.4% |
| Operating Free Cash Flow | -$22.20M | 20.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.33 | 0.86 | 1.00 | 1.17 | -20.40% |
| Price to Sales | 3.76 | 2.41 | 2.96 | 3.86 | -16.05% |
| Price to Tangible Book Value | 1.81 | 1.23 | 1.45 | 1.17 | -41.50% |
| Enterprise Value to EBITDA | -15.34 | -6.97 | -11.44 | -15.08 | -29.92% |
| Return on Equity | -43.7% | -25.7% | -22.4% | -24.6% | -64.66% |
| Total Debt | $33.00M | $31.53M | $28.62M | $27.39M | -69.39% |
No podcast episodes available.
FLDM earnings call for the period ending March 31, 2020.
FLDM earnings call for the period ending December 31, 2019.
FLDM earnings call for the period ending September 30, 2019.
FLDM earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
